Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GC Group
Yongin-si, Gyeonggi-do, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
GC Group is a commercial-stage biotech company with multiple marketed products including the world's first pandemic hemorrhagic fever vaccine, Korea's first flu vaccine, world's second Hunter syndrome treatment, varicella-zoster vaccine, world's third hepatitis B vaccine, and third-generation recombinant hemophilia treatment
- Therapeutic areas
- OncologyHematologyInfectious DiseasesRare Diseases
- Modalities
- VaccineBiologicCell therapyGene therapyRecombinant proteinMonoclonal antibodyStem cell therapy
- Industry
- Biotech
02
Partnerships
IDRI (Infectious Disease Research Institute)
Beyond the preview
Go deeper on GC Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC Group.